ライフサイエンスコーパス: endothelin-converting enzyme

1 th virulence and has a putative action as an endothelin-converting enzyme.

2 Here, we have identified neural endothelin-converting enzyme 1 (ECE-1) as a key regulato

3 ned whether agonist degradation by endosomal endothelin-converting enzyme 1 (ECE-1) controls SSTR2A t

4 etalloendopeptidases, which includes NEP and endothelin-converting enzyme 1 (ECE-1), an enzyme involv

5 approaches, we identified and characterized endothelin-converting enzyme 1 (ECE1) in a human neurobl

6 empty spiracles homeobox 1 [EMX1], AK055957, endothelin-converting enzyme 1 [ECE1], phosphofructokina

7 ns only 18 genes, among which Ece1, encoding endothelin-converting enzyme 1, stands out as a candidat

8 -1 expression, indicating the presence of an endothelin-converting enzyme 1/endothelin 1-SphK positiv

9 ng is sequential and involved meprin B, ECE (endothelin-converting enzyme) 1, and ANPEP (aminopeptida

10 Endothelin converting enzyme-1 (ECE-1) catalyzes the pro

11 t homology with neutral endopeptidase 24.11, endothelin converting enzyme-1 (ECE-1), and the PEX gene

12 erformed on the gro1, B-factor, adlican, and endothelin converting enzyme-1 genes and confirmed micro

13 lly generated from its inactive precursor by endothelin-converting enzyme-1 (ECE-1) and acts on the e

14 is report, we describe the identification of endothelin-converting enzyme-1 (ECE-1) as a novel Abeta-

15 itro models we have previously characterized endothelin-converting enzyme-1 (ECE-1) as an Abeta-degra

16 Endothelin-converting enzyme-1 (ECE-1) degrades NT in ac

17 We report that endothelin-converting enzyme-1 (ECE-1) degrades substanc

18 d selective non-peptidic inhibitors of human endothelin-converting enzyme-1 (ECE-1) have been designe

19 We report a major role for endothelin-converting enzyme-1 (ECE-1) in controlling su

20 ported the intracellular localization of the endothelin-converting enzyme-1 (ECE-1) in human umbilica

21 more, we have previously shown that both the endothelin-converting enzyme-1 (ECE-1) inhibitor, phosph

22 Endothelin-converting enzyme-1 (ECE-1) is a membrane-bou

23 Previous work has shown that endothelin-converting enzyme-1 (ECE-1) is able to reduce

24 Endothelin-converting enzyme-1 (ECE-1) is the enzyme pre

25 Endothelin-converting enzyme-1 (ECE-1) processes big end

26 Endothelin-converting enzyme-1 (Ece-1), a crucial compon

27 eptide is the conversion of its precursor by endothelin-converting enzyme-1 (ECE-1), a metalloproteas

28 ss has been linked to enhanced expression of endothelin-converting enzyme-1 (ECE-1, the enzyme that c

29 We report that isoforms of endothelin-converting enzyme-1 (ECE-1a-d) are present in

30 To investigate the phosphorylation of human endothelin-converting enzyme-1 (hECE-1) and identify pot

31 Endothelin-converting enzyme-1 and -2 (ECE-1 and -2) are

32 t inhibition of SphK leads to suppression of endothelin-converting enzyme-1 expression, indicating th

33 our murine model by using phospharamidon, an endothelin-converting enzyme-1 inhibitor; knocking down

34 converting enzyme-1 inhibitor; knocking down endothelin-converting enzyme-1 mRNA; or blocking the bin

35 red liver led to a decrease in expression of endothelin-converting enzyme-1, a critical regulator of

36 rocessing, such as insulin degrading enzyme, endothelin-converting enzyme-1, neprilysin and alpha-sec

37 Among them, endothelin-converting enzyme-2 (ECE-2) is a good candida

38 Endothelin-converting enzyme-2 (ECE-2), a member of M13

39 Endothelin-converting enzyme-2 (ECE-2), which is express

40 We now show that superoxide can inhibit endothelin-converting enzyme activity (ECE) and decrease

41 d reduce AD neuropathology through increased endothelin-converting enzyme activity.

42 a-amyloid in the brain but confirm roles for endothelin-converting enzyme and neprilysin and indicate

43 amyloid levels are significantly elevated in endothelin-converting enzyme and neprilysin knock-out mi

44 increasing the rate of Abeta degradation by endothelin-converting enzyme and not by activating nonam

45 Big ET-1 is cleaved in vivo by ECE-1 (endothelin-converting enzyme), and big ET-3 is also clea

46 In contrast, phosphoramidon, an inhibitor of endothelin-converting enzyme, did not significantly chan

47 inc protease that is homologous to mammalian endothelin-converting enzyme ECE-1.

48 Members of the endothelin-converting enzyme (ECE) family are considered

49 The neprilysin (NEP)/endothelin-converting enzyme (ECE) family of metalloprot

50 A novel putative endothelin-converting enzyme (ECE) has been cloned from

51 We therefore investigated the effects of endothelin-converting enzyme (ECE) inhibition and endoth

52 When tested as inhibitors towards endothelin-converting enzyme (ECE), both LFHs <3 kDa exe

53 Metalloproteases, including endothelin-converting enzyme (ECE)-1 and -2, reside with

54 he roles of ET(A) and ET(B) receptors and of endothelin-converting enzyme (ECE)-1 in ET-1-induced vas

55 ermining the ultrastructural localization of endothelin-converting enzyme (ECE)-1.

56 tudies have identified a polymorphism in the endothelin-converting enzyme (ECE)-1b promoter (-338C/A)

57 fic contribution of Abeta-degrading protease endothelin-converting enzyme (ECE-1) to synaptic/endosom

58 teolytic processing of precursor peptides by endothelin-converting enzymes (ECEs).

59 ngiotensin-converting enzyme, neprilysin and endothelin-converting enzyme function as vasopeptidases

60 Deletion of Edn1, Ednra or endothelin-converting enzyme in mice causes perinatal le

61 est that the combination of low-dose CsA and endothelin-converting enzyme inhibition may prove useful

62 receptor antagonist; and phosporamindon, an endothelin converting enzyme inhibitor in the eyes of di

63 ld be significantly improved by combining an endothelin-converting enzyme inhibitor with low-dose CsA

64 i.m. on day 2), low-dose CsA (25 mg/kg), an endothelin-converting enzyme inhibitor, phosphoramidon (

65 sAbeta-degrading enzymes examined, including endothelin-converting enzyme, insulin-degrading enzyme,

66 a nicotinic receptor (CHRNG, 6 subjects) and endothelin converting enzyme-like 1 (ECEL1, 4 subjects).

67 ltiplex consanguineous family to identify in endothelin-converting enzyme-like 1 (ECEL1) mutations th

68 tor antagonism or inhibition of the specific endothelin-converting enzymes may, therefore, represent

69 f several degradative enzymes, including the endothelin-converting enzymes, neprilysin, insulin-degra

70 nists (BQ123 plus BQ788) or by inhibition of endothelin-converting enzyme (phosphoramidon or SM19712)

71 However, they activated endothelin-converting enzyme to 180% of control levels,

72 ty to mammalian metallopeptidases, including endothelin-converting enzyme, which converts a potent va

73 ession selectively increased the activity of endothelin-converting enzyme, which degrades Abeta.

74 Decreasing ET-1 levels by inhibiting endothelin-converting enzyme with phosphoramidon normali